Previous 10 | Next 10 |
RightSource is Charles River’s insourced, purpose-built lab offering that provides industry-leading expertise conveniently placed within a client’s facility Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufac...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Charles River To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 28, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm...
2023-05-23 06:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-13 14:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-11 23:09:52 ET Summary In the past year, Charles River (-13.59%) has trailed both the S&P 500 (+4.83%) in addition to the healthcare index, IXHC (+21.81%). This reflects a -44.57% YoY free cash flow decline owing to material reductions in net income from 2021-22. I...
2023-05-11 13:27:10 ET Charles River Laboratories International, Inc. (CRL) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Todd Spencer – Vice President-Investor Relations Jim Foster – Chairman, President and Chief Executi...
2023-05-11 07:02:35 ET Charles River Laboratories press release ( NYSE: CRL ): Q1 Non-GAAP EPS of $2.78 beats by $0.19 . Revenue of $1.03B (+12.7% Y/Y) beats by $43.94M . FY23 Guidance: Non-GAAP EPS of $9.90-$10.90 vs $10.24 consensus For further deta...
– First-Quarter Revenue of $1.03 Billion – – First-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.78 – – Updates 2023 Guidance – Charles River Laboratories International, Inc. (NYSE: CRL) today...
2023-05-10 14:29:45 ET Charles River Laboratories ( NYSE: CRL ) is scheduled to announce Q1 earnings results on Thursday, May 11th, before market open. The consensus EPS Estimate is $2.59 (-5.8% Y/Y) and the consensus Revenue Estimate is $986.06M (+7.9% Y/Y). Over the ...
Company also announces partner lab initiative to expand global coverage Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix® NGS). A...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good...